Shionogi's COVID Pill Shows Promise in Reducing Transmission

A Phase 3 trial demonstrates that the antiviral ensitrelvir significantly lowers symptomatic COVID-19 cases in household contacts.

• The SCORPIO-PEP trial involved approximately 2,400 participants across the US, South America, Africa, and Asia.
• Ensitrelvir, known as Xocova, achieved a statistically significant reduction in symptomatic infections compared to a placebo.
• Participants began treatment within three days of exposure to a symptomatic household member and continued for five days.
• Ensitrelvir was well tolerated with no new safety concerns, highlighting its potential as a preventive option.
• Japan granted full approval for Xocova in March 2024, though much of the purchased supply remains unused.

3 Articles

ContagionLive Denver Gazette